Neuron23 Inc. is a clinical-stage biotechnology company headquartered at 343 Oyster Point Blvd, Suite 120, South San Francisco, California 94080, focused on developing precision medicines for genetically defined neurological and immunological diseases. Founded in 2020, the company combines cutting-edge data science, human genetics, and innovative clinical approaches to address the underlying causes of neurodegenerative diseases rather than just treating symptoms[1].
The company raised a $96.5 million Series D financing in June 2025, providing substantial runway for the NEULARK Phase 2 trial and pipeline expansion [2].
The company is led by a team with proven success in both science and business, leveraging expertise in genomics, artificial intelligence, and drug discovery to advance precision medicine for neurological diseases. The leadership includes industry veterans from companies such as Genentech, Biogen, and Google-backed healthcare ventures.
Neuron23's research focuses on:
| Drug Candidate | Target | Indication | Development Phase |
|---|---|---|---|
| NEU-411 | LRRK2 (Leucine-Rich Repeat Kinase 2) | Parkinson's disease | Phase 2 (NEULARK trial) |
| N23-002 | GBA (Glucocerebrosidase) | Parkinson's disease | Preclinical |
NEU-411 is a brain-penetrant, potent, and selective LRRK2 kinase inhibitor designed to treat LRRK2-driven Parkinson's disease — a genetically defined subset of the condition. LRRK2 mutations are among the most common genetic causes of familial PD, particularly the G2019S variant which accounts for approximately 5-10% of all PD cases[1].
Mechanism: NEU-411 is an ATP-competitive inhibitor of LRRK2 kinase activity. It reduces phosphorylation of LRRK2 substrates including Rab GTPases (Rab3, Rab8, Rab10, Rab12), thereby normalizing the vesicular trafficking, autophagy, and lysosomal function that are disrupted by pathogenic LRRK2 mutations.
Clinical Development:
Competitive Position: NEU-411 competes with BIIB122 (Biogen/Denali, Phase 2b LUMA trial) and G007-LK (Vanqua Bio/Genentech, preclinical). Neuron23 differentiates through its precision medicine approach — exclusively enrolling LRRK2 mutation carriers — and its novel chemical scaffold with favorable selectivity profiles.
For a comprehensive overview, see LRRK2 Inhibitors for Parkinson's Disease and LRRK2 Kinase Pathway in Parkinson's Disease.
Neuron23's GBA program targets patients with glucocerebrosidase (GBA) mutations, which are among the most significant genetic risk factors for Parkinson's disease. GBA mutations are found in approximately 5-15% of sporadic PD cases and up to 40% of certain ethnic populations [8]. The N23-002 program is in preclinical development.
Neuron23 employs several key technologies:
In June 2025, Neuron23 announced the closing of a $96.5 million Series D financing, providing substantial runway for clinical development and pipeline expansion [2]. Previous funding rounds include:
| Trial Name | Phase | Indication | Status | NCT Number |
|---|---|---|---|---|
| NEULARK | Phase 2 | Early Parkinson's disease (LRRK2+) | Recruiting | NCT06436589 |
Neuron23 maintains collaborations with leading academic institutions and research organizations to advance their precision medicine approach for Parkinson's disease, including partnerships with:
The company maintains a page for current career opportunities, seeking talented individuals with expertise in drug discovery, neuroscience, and bioinformatics.
Alessi DR et al. LRRK2 and Parkinson's Disease: From Genetics to Therapy. Brain. 2023. ↩︎